We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Stands Firm on Proposed Withdrawal of AMAG’s Makena Despite Analysis Findings
FDA Stands Firm on Proposed Withdrawal of AMAG’s Makena Despite Analysis Findings
The FDA has not wavered on its October 2020 call for AMAG Pharmaceuticals to withdraw its preterm birth progestin drug Makena and generic versions of it even after a meta-analysis from multiple trials found that it reduced preterm birth before 34 weeks.